CNTB — CONNECT BIOPHARMA HLDGS LTD
As of Q2 2026, 18 SEC-registered investment managers reported holding CNTB (CONNECT BIOPHARMA HLDGS LTD) in their latest 13F filings, with a combined reported value of $4.97M across 2.10M shares. That is +127.8% by share count (+1.18M shares) versus the previous quarter, while reported value moved +105.8%. Ownership is concentrated: the five largest holders account for 83.8% of reported value and the top ten for 96.8%.
Compared with the prior quarter, 9 opened new positions, 7 added to existing stakes, 2 trimmed, 3 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
CNTB is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| BlackRock Inc history | Q2 2026 | 871.65K | $2.07M | 0.00% | New |
| Marshall Wace history | Q2 2026 | 335.64K | $798.83K | 0.00% | Add |
| Geode Capital Management history | Q2 2026 | 257.45K | $612.74K | 0.00% | Add |
| Two Sigma Investments history | Q2 2026 | 199.38K | $474.53K | 0.00% | Add |
| Citadel Advisors history | Q1 2026 | 112.67K | $295.21K | 0.00% | Add |
| Renaissance Technologies history | Q2 2026 | 87.30K | $207.77K | 0.00% | Reduce |
| Northern Trust Corp history | Q2 2026 | 82.86K | $197.21K | 0.00% | New |
| UBS Group AG history | Q2 2026 | 66.45K | $158.15K | 0.00% | Add |
| Millennium Management history | Q2 2026 | 43.71K | $104.03K | 0.00% | Reduce |
| Bank of America Corp history | Q2 2026 | 40.92K | $97.39K | 0.00% | Add |
| Charles Schwab Investment Management history | Q2 2026 | 36.76K | $87.49K | 0.00% | New |
| Goldman Sachs Group history | Q1 2026 | 29.83K | $78.16K | 0.00% | New |
| BNY Mellon history | Q2 2026 | 23.95K | $57.01K | 0.00% | New |
| Point72 Asset Management history | Q1 2026 | 19.77K | $51.79K | 0.00% | Add |
| Wells Fargo & Co history | Q2 2026 | 13.24K | $31.51K | 0.00% | New |
| JPMorgan Chase & Co history | Q2 2026 | 11.72K | $27.89K | 0.00% | New |
| Morgan Stanley history | Q2 2026 | 8.64K | $20.56K | 0.00% | Add |
| Citigroup Inc history | Q2 2026 | 6.99K | $16.63K | 0.00% | Add |
| Legal & General Investment Management America history | Q2 2026 | 2.42K | $5.75K | 0.00% | New |
| Fidelity Management & Research (FMR) history | Q2 2026 | 314 | $747 | 0.00% | New |
New Positions (Q2 2026)
- BlackRock Inc 871.65K sh · $2.07M
- Northern Trust Corp 82.86K sh · $197.21K
- Charles Schwab Investment Management 36.76K sh · $87.49K
- BNY Mellon 23.95K sh · $57.01K
- Wells Fargo & Co 13.24K sh · $31.51K
- JPMorgan Chase & Co 11.72K sh · $27.89K
- Legal & General Investment Management America 2.42K sh · $5.75K
- Fidelity Management & Research (FMR) 314 sh · $747
- T. Rowe Price Associates 12.47K sh · $30
Fully Exited (vs previous quarter)
- Citadel Advisors sold 112.67K sh · $295.21K
- Goldman Sachs Group sold 29.83K sh · $78.16K
- Point72 Asset Management sold 19.77K sh · $51.79K
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| BlackRock Inc | — | — | — | 871.65K |
| Marshall Wace | 58.03K | 128.37K | 66.01K | 335.64K |
| Geode Capital Management | 23.32K | 23.32K | 32.13K | 257.45K |
| Two Sigma Investments | — | — | 47.47K | 199.38K |
| Renaissance Technologies | 158.20K | 143.10K | 120.70K | 87.30K |
| Northern Trust Corp | — | — | — | 82.86K |
| UBS Group AG | 201 | 3.17K | 33 | 66.45K |
| Millennium Management | — | 47.05K | 474.60K | 43.71K |
| Bank of America Corp | — | — | 15.67K | 40.92K |
| Charles Schwab Investment Management | — | — | — | 36.76K |
| BNY Mellon | — | — | — | 23.95K |
| Wells Fargo & Co | — | — | — | 13.24K |
| JPMorgan Chase & Co | 121 | 121 | — | 11.72K |
| Morgan Stanley | 100 | 2.21K | 3.59K | 8.64K |
| Citigroup Inc | 4.21K | — | 1 | 6.99K |
| Legal & General Investment Management America | — | — | — | 2.42K |
| Fidelity Management & Research (FMR) | — | — | — | 314 |
| T. Rowe Price Associates | — | — | — | 12.47K |
| Citadel Advisors | — | 99.49K | 112.67K | — |
| Point72 Asset Management | — | 16.50K | 19.77K | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details